Skip to main content
Hansoh Pharmaceutical Group Company Limited logo

Hansoh Pharmaceutical Group Company Limited — Investor Relations & Filings

Ticker · 3692 ISIN · KYG549581067 LEI · 254900Q6MR00EBXTPF42 HKEX Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 3692

About Hansoh Pharmaceutical Group Company Limited

http://www.hspharm.com

Hansoh Pharmaceutical Group Company Limited is a leading innovation-driven biopharmaceutical enterprise engaged in the research, development, manufacturing, and commercialization of life-changing medicines. The company focuses on major therapeutic areas, including Oncology, Anti-infectives, CNS Diseases (psychiatric and neurological disorders), Metabolic Diseases (such as diabetes and obesity), and Autoimmune Diseases. Hansoh Pharma leverages highly efficient R&D capabilities, covering small molecules, peptides, and biologics, supported by eight cutting-edge technology platforms, including Antibody Drug Conjugation and RNAi. Its robust product portfolio features innovative drugs such as the anti-tumor agent Ameile (aumolertinib) and the metabolic disease treatment Fulaimei (PEG-loxenatide). The company maintains a deep clinical pipeline with over 40 innovative drug candidates, underscoring its commitment to continuous innovation.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - THE NMPA HAS GRANTED BREAKTHROUGH-THERAPY-DESIGNATED DRUG FOR FOURTH-GENERATION EGFR-TKI HS-10504 TABLETS FOR NSCLC
Regulatory Filings Classification · 88% confidence The document is a short voluntary announcement under Hong Kong Exchange rules regarding regulatory approval (breakthrough therapy designation) from China’s NMPA. It does not contain financial statements, meeting materials, voting results, or management changes. It is not a formal financial or legal report but a general disclosure, fitting the Regulatory Filings (RNS) fallback category.
2026-05-21 English
CHANGES OF JOINT COMPANY SECRETARY, AUTHORIZED REPRESENTATIVE AND PROCESS AGENT
Board/Management Information Classification · 90% confidence The document is a formal announcement on Hong Kong Exchanges regarding the resignation and appointment of a joint company secretary, authorized representatives, and process agents – i.e., changes in corporate officers. This matches the Board/Management Information category (MANG).
2026-05-15 English
VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR HS-10541 TABLETS ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Regulatory Filings Classification · 83% confidence The document is a Hong Kong Stock Exchange voluntary announcement regarding regulatory approval for a clinical trial (HS-10541 tablets) by the National Medical Products Administration. It does not contain financial results, management changes, dividends, proxy materials, or detailed financial statements. It is a general regulatory announcement/disclosure. Therefore, it falls under the fallback category Regulatory Filings (RNS).
2026-05-13 English
VOLUNTARY ANNOUNCEMENT - THE NMPA HAS GRANTED BREAKTHROUGH-THERAPY-DESIGNATED DRUG FOR B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE HS-20093 FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Regulatory Filings Classification · 80% confidence The document is titled a “Voluntary Announcement” by Hansoh Pharmaceutical and details the NMPA’s approval of a drug as a Breakthrough-Therapy-Designated Drug. It is a general regulatory announcement about product approval (not a financial report, earnings release, management change, dividend, share transaction, etc.). Therefore it best fits the catch-all “Regulatory Filings” category (code RNS).
2026-05-11 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a monthly return filing to the Hong Kong Exchanges and Clearing Limited (HKEX) detailing movements in securities for the issuer Hansoh Pharmaceutical Group Company Limited for the month ended April 30, 2026. It includes detailed information on authorized share capital, issued shares, treasury shares, public float sufficiency confirmation, and movements in issued shares including allotments pursuant to RSU schemes. The document is a regulatory compliance filing related to share capital and securities movements rather than a financial report, earnings release, or management discussion. It is not an announcement of a report publication but a substantive regulatory filing. The document fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement and compliance document related to securities movements under HKEX rules.
2026-05-04 English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO THE RESTRICTED SHARE UNIT SCHEME
Transaction in Own Shares Classification · 95% confidence The document is a voluntary announcement by Hansoh Pharmaceutical Group regarding a share purchase under a restricted share unit scheme. It details the number of shares purchased, trade and settlement dates, and the balance of shares held by the RSU Trustee. The document is short (3318 characters) and focuses on a specific transaction related to share purchases for an employee incentive scheme. It does not contain financial statements, earnings data, or regulatory certifications. It is not an annual or interim report, nor a call transcript or management discussion. The content fits the description of a Transaction in Own Shares (POS), which covers company buybacks or share purchases related to employee schemes. Therefore, the appropriate classification is POS with high confidence.
2026-04-30 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.